Premium
Systemic therapeutic options for severe atopic dermatitis
Author(s) -
Bußmann Caroline,
Bieber Thomas,
Novak Natalija
Publication year - 2009
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/j.1610-0387.2008.06834.x
Subject(s) - medicine , azathioprine , tacrolimus , atopic dermatitis , methotrexate , dermatology , adverse effect , mycophenolate , systemic therapy , dupilumab , intensive care medicine , immunology , transplantation , pharmacology , disease , surgery , cancer , breast cancer
Summary Systemic therapy of severe atopic dermatitis (AD) is difficult in some cases, because the use of immunosuppressive agents such as cyclosporine A, mofetil mycophenolate, tacrolimus, and azathioprine is limited by adverse reactions or contraindications. Recent reports suggest a helpful role for biologics, methotrexate, anti‐IgE antibodies, and immunotherapy. We review the modes of action, as well as advantages and disadvantages of current and new systemic therapeutic options for severe AD.